- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01772693
ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease
A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease.
This is a feasibility study to evaluate the safety and initial effectiveness of unilateral ExAblate thermal ablation of the Vim thalamic nucleus of subjects suffering from medication-refractory, idiopathic, tremor-dominant PD, using the ExAblate Transcranial system compared to a Sham Vim thalamotomy procedure.
Data will be collected to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its full clinical efficacy. The Sham treatment data will be used to evaluate placebo effect from treatment.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- University of Virginia
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98122
- Swedish Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men and women, age 30 years and older
- Subjects who are able and willing to give informed consent and able to attend all study visits
- Subjects with a diagnosis of idiopathic PD as confirmed from clinical history and examination by a movement disorder neurologist at the site
- Subject demonstrates a severe resting tremor or postural/action as measured by UPDRS
- Subject exhibits a significant disability from their PD tremor despite medical treatment
- Subjects should be on a stable dose of all PD medications for 30 days prior to study entry
- Subject is able to communicate sensations during the ExAblate Transcranial procedure
Exclusion Criteria:
- Subjects with unstable cardiac status
- Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse
- Severe hypertension
- Subjects with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
- Known intolerance or allergies to the MRI contrast agent including advanced kidney disease or severely impaired renal function
- Significant claustrophobia that cannot be managed with mild medication
- Current medical condition resulting in abnormal bleeding and/or coagulopathy
- Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage
- History of intracranial hemorrhage
- History of multiple strokes, or a stroke within past 6 months
- Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment
- Are participating or have participated in another clinical trial in the last 30 days
- Subjects unable to communicate with the investigator and staff
- Subjects with a history of seizures within the past year
- Subjects with brain tumors
- Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment
- Subjects who have had deep brain stimulation or a prior stereotactic ablation of the basal ganglia
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: ExAblate Transcranial MRgFUS
ExAblate Transcranial MR guided Focused Ultrasound
|
ExAblate Transcranial MR Guided Focused Ultrasound
Altri nomi:
|
Comparatore fittizio: Sham ExAblate Transcranial MRgFUS
Sham treatment with ExAblate MR guided Focused Ultrasound
|
Sham ExAblate Transcranial MR Guided Focused Ultrasound
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Adverse Events
Lasso di tempo: Month 3
|
Evaluate of adverse events (AEs) associated with the ExAblate Transcranial thalamotomy of medication-refractory, tremor-dominant PD during the ExAblate treatment. Primary safety analyses are reported in the adverse events module. |
Month 3
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Tremor Motor Score Percent Change From Baseline.
Lasso di tempo: Baseline, Month 3
|
The percent change from baseline to Month 3 follow-up in upper extremity Tremor-Motor scores for the treated side is a sub-scale of Clinical Rating Scale for Tremor (CRST) Part A and Part B sum that was used to measure treated-side upper extremity tremor changes over time.
Tremor-motor scores range from 0-32 points.
Individual subject's scores at Baseline and 3 Months were used to calculate percent change from baseline and averaged across subjects.
High percent change from baseline is better (shows improvement).
|
Baseline, Month 3
|
Tremor Motor Scores - Clinical Rating Scale for Tremor - Treated Side Upper Extremity Parts A & B.
Lasso di tempo: Baseline, Month 3, Month 12
|
Upper extremity Tremor-Motor score for the treated side is a sub-scale of Clinical Rating Scale for Tremor (CRST) Part A and Part B sum that measures treated-side upper extremity tremor changes over time.
Tremor-motor scores range from 0-32 points for each side with lower scores being a better outcome.
Subject's Tremor-Motor scores for the test and sham control groups were averaged at each study visit.
|
Baseline, Month 3, Month 12
|
Functional Disabilities - Clinical Rating Scale for Tremor Part C - Functional Disabilities
Lasso di tempo: Baseline, Month 3, Month 12
|
The Clinical Rating Scale for Tremor (CRST) Part C is a measure of functional disability due to tremor.
The Clinical Rating Scale for Tremor Part C consists of 8 items each scored from 0 to 4. Thus, the total score summed ranges from 0 to 32 and provides an overall assessment of activities of daily living.
Low scores on the Clinical Rating Scale for Tremor (CRST) Part C are better.
Low scores show improvement in functional disabilities compared to higher scores.
|
Baseline, Month 3, Month 12
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jeff Elias, M.D., University of Virginia
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PD001
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su ExAblate Transcranial MRgFUS
-
Yonsei UniversityCompletato
-
InSightecAttivo, non reclutanteDolore neuropatico del trigeminoStati Uniti
-
InSightecCompletato
-
Matthew BucknorFocused Ultrasound FoundationReclutamentoOsteoma osteoideStati Uniti
-
Istituto Ortopedico RizzoliCompletatoOsteoartrite | Artrosi della mano | Artrosi dell'ancaItalia
-
Matthew BucknorFocused Ultrasound Foundation; InSightec-TxSonicsReclutamentoSarcoma pleomorfo indifferenziatoStati Uniti
-
University of Roma La SapienzaSconosciutoTumori maligni secondari dell'ossoItalia
-
InSightecCompletatoTremore EssenzialeCanada, Stati Uniti, Giappone, Corea, Repubblica di
-
University of FloridaReclutamento
-
Istituto Ortopedico RizzoliCompletatoOsteoartrite | Artrosi, ginocchio | Artrite al ginocchioItalia